Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts-Reference-Cited by-同舟云学术

Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts

Published:2021-07-29 Issue:10 Volume:96 Page:1211-1222
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Mehta‐Shah Neha¹²^ORCID,Lunning Matthew A.¹³,Moskowitz Alison J.¹,Boruchov Adam M.⁴,Ruan Jia⁵,Lynch Peggy¹,Hamlin Paul A.¹^ORCID,Leonard John⁵,Matasar Matthew J.¹,Myskowski Patricia L.⁶,Marzouk Evan¹,Nair Sumithra¹,Sholklapper Tamir¹,Minnal Veena¹,Palomba Maria L.¹,Vredenburgh James⁴,Kumar Anita¹,Noy Ariela¹,Straus David J.¹,Zelenetz Andrew D.¹,Schoder Heiko⁷,Rademaker Jurgen⁷,Schaffer Wendy¹,Galasso Natasha¹,Ganesan Nivetha¹,Horwitz Steven M.¹

Affiliation:

1. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA

2. Washington University School of Medicine in St. Louis St. Louis Missouri USA

3. Department of Medicine University of Nebraska Medical Center Omaha Nebraska USA

4. Department of Medicine St. Francis Medical Center Hartford Connecticut USA

5. Department of Medicine Weill Cornell Medical Center New York New York USA

6. Dermatology Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA

7. Department of Radiology Memorial Sloan Kettering Cancer Center New York New York USA

Funder

American Society of Hematology

Lymphoma Research Foundation

National Cancer Institute

National Comprehensive Cancer Network

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26288

Reference50 articles.

1. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

2. Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

3. Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

4. Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant.

5. Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Failing Forward in Peripheral T-Cell Lymphoma;Journal of Clinical Oncology;2024-05-10

2. Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management;American Journal of Hematology;2024-02-02

3. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas;Clinical Lymphoma Myeloma and Leukemia;2024-02

4. A Phase I Study of Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone in Patients with Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas;2024

5. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments;Frontiers in Immunology;2023-10-05